Radiopharm Theranostics Ltd (RADX) EPS (Basic) (2023 - 2026)

Radiopharm Theranostics (RADX) has reported EPS (Basic) for 4 consecutive years, with -$0.0 the latest figure, recorded in Q2 2026.

• On a quarterly basis, EPS (Basic) rose 98.13% year-over-year to -$0.0 in Q2 2026; TTM through Jun 2026 was -$0.04, a N/A change from a year earlier, with the FY2026 full-year figure at -$0.0, down 16.52% from the prior year.
• EPS (Basic) was -$0.0 for Q2 2026 at Radiopharm Theranostics, up from -$0.02 in the prior quarter.
• Over five years, EPS (Basic) peaked at -$0.0 in Q2 2026 and troughed at -$0.11 in Q2 2023.
• A 4-year average of -$0.03 and a median of -$0.01 in 2024 frame the typical range for EPS (Basic).
• Across the five-year window, EPS (Basic) jumped 99.4% in 2024 and slumped 2589.3% in 2025, its largest moves.
• Over 4 years, EPS (Basic) stood at -$0.11 in 2023, then jumped by 99.4% to -$0.0 in 2024, then sank by 2589.3% to -$0.02 in 2025, then jumped by 98.13% to -$0.0 in 2026.
• The last three EPS (Basic) figures came in at -$0.0 (Q2 2026), -$0.02 (Q2 2025), and -$0.0 (Q2 2024), per Business Quant data.